In the Journal of Medicinal Chemistry (More information), the scientists published the macrocyclization of binding molecules for the FK506-binding protein 51. This protein is an important risk factor for diseases like depression, obesity and chronic pain. “However, identifying selectively binding molecules with drug-like properties has been the key challenge so far”, explains Prof. Felix Hausch from the Department of Chemistry. “Based on our structural insights into the binding mode of FKBP51 ligands we could design a macrocyclization approach, which alleviated key limitations of the previously available FKBP51 binders”.
In a landmark study supported by the Pioneer-Fund (More information) and the LOEWE consortium TRABITA (More information) and now published in the prestigious journal Angewandte Chemie International Edition (More information), the Hausch lab went on to additionally identify a new macrocyclic class of FKBP51 binders, which for the first time were able to discriminate against the closely related homologs FKBP12 and FKBP12.6. “This could be key to avoid adverse side effect caused by FKBP12/12.6 inhibition”, says Professor Hausch.
Taken together, these two findings provide the key impetus towards the development of a clinical candidate for FKBP51 ready for testing in human patients. This is currently prosecuted within funding of the VIP+ grant Fit4Fat recently awarded to the Hausch lab (More information). The methods of macrocyclization can also be applied to drug development for COVID19, as currently pursued in Pioneer Fund project CoMaProtInhib (More information).